Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.

  title={Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.},
  author={A S Lok and Fabien Zoulim and Stephen L. Locarnini and Angeline Bartholomeusz and Marc G Ghany and Jean-Michel Pawlotsky and Y -F Liaw and Masashi Mizokami and Carla Kuiken},
  volume={46 1},
Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs). Sustained viral suppression is rarely achieved after withdrawal of a 48-week course of NA therapy, necessitating long, and in many cases, indefinite treatment with increasing risk of development of drug resistance. Antiviral resistance and poor adherence are the most important factors… CONTINUE READING
Highly Influential
This paper has highly influenced 15 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS


Publications citing this paper.
Showing 1-10 of 194 extracted citations

virus reverse transcriptase sequence variant database for sequence nalysis and mutation discovery

oo-Yon Rheea, Severine Margeridon-Thermeta, +6 authors Robert W. Shafera
View 10 Excerpts
Highly Influenced

Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment.

The Journal of general virology • 2015
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 84 references

Telbivudine (LDT) vs. lamivudine for chronic hepatitis B: first-year results from the International Phase III Globe Trial [Abstract

C Lai, E Gane, +3 authors E Heathcote
HEPATOLOGY 2005;42(Suppl):748A. HEPATOLOGY, • 2007

A double-blind placebo-controlled study of emtricitabine in chronic hepatitis

SG Lim, TM Ng, +3 authors P Husa
B. Arch Intern Med • 2006

Similar Papers

Loading similar papers…